320 related articles for article (PubMed ID: 29282880)
1. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.
Huang B; Kuan PF
Pharm Stat; 2018 May; 17(3):202-213. PubMed ID: 29282880
[TBL] [Abstract][Full Text] [Related]
2. Quantifying treatment differences in confirmatory trials under non-proportional hazards.
Jiménez JL
J Appl Stat; 2022; 49(2):466-484. PubMed ID: 35707213
[TBL] [Abstract][Full Text] [Related]
3. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
4. Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint.
Rulli E; Ghilotti F; Biagioli E; Porcu L; Marabese M; D'Incalci M; Bellocco R; Torri V
Br J Cancer; 2018 Dec; 119(12):1456-1463. PubMed ID: 30420618
[TBL] [Abstract][Full Text] [Related]
5. Dynamic RMST curves for survival analysis in clinical trials.
Liao JJZ; Liu GF; Wu WC
BMC Med Res Methodol; 2020 Aug; 20(1):218. PubMed ID: 32854619
[TBL] [Abstract][Full Text] [Related]
6. [Application of restricted mean survival time in clinical follow-up study].
Yang ZJ; Lyu JJ; Hou YW; Chen Z
Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Feb; 40(2):247-250. PubMed ID: 30744281
[TBL] [Abstract][Full Text] [Related]
7. Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.
Pak K; Uno H; Kim DH; Tian L; Kane RC; Takeuchi M; Fu H; Claggett B; Wei LJ
JAMA Oncol; 2017 Dec; 3(12):1692-1696. PubMed ID: 28975263
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials.
Trinquart L; Jacot J; Conner SC; Porcher R
J Clin Oncol; 2016 May; 34(15):1813-9. PubMed ID: 26884584
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity Analysis for Restricted Mean Survival Time When Survival Curves Have Divergent Tails.
Ueno K; Morita S
Ther Innov Regul Sci; 2023 May; 57(3):467-471. PubMed ID: 36596962
[TBL] [Abstract][Full Text] [Related]
10. Performance of Restricted Mean Survival Time Based Methods and Traditional Survival Methods: An Application in an Oncological Data.
Huang Q; Tian C
Comput Math Methods Med; 2022; 2022():7264382. PubMed ID: 36619796
[TBL] [Abstract][Full Text] [Related]
11. Restricted mean survival time as a summary measure of time-to-event outcome.
Hasegawa T; Misawa S; Nakagawa S; Tanaka S; Tanase T; Ugai H; Wakana A; Yodo Y; Tsuchiya S; Suganami H;
Pharm Stat; 2020 Jul; 19(4):436-453. PubMed ID: 32072769
[TBL] [Abstract][Full Text] [Related]
12. Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer.
Liang F; Zhang S; Wang Q; Li W
Ann Oncol; 2018 May; 29(5):1320-1324. PubMed ID: 29788167
[TBL] [Abstract][Full Text] [Related]
13. The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial.
Abulizi X; Ribaudo HJ; Flandre P
J Acquir Immune Defic Syndr; 2019 May; 81(1):44-51. PubMed ID: 30789450
[TBL] [Abstract][Full Text] [Related]
14. Cancer Biology and Survival Analysis in Cancer Trials: Restricted Mean Survival Time Analysis versus Hazard Ratios.
A'Hern RP
Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):e75-e80. PubMed ID: 29776805
[TBL] [Abstract][Full Text] [Related]
15. The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials.
Péron J; Roy P; Ozenne B; Roche L; Buyse M
JAMA Oncol; 2016 Jul; 2(7):901-5. PubMed ID: 27124210
[TBL] [Abstract][Full Text] [Related]
16. Measuring Survival Benefit in Health Technology Assessment in the Presence of Nonproportional Hazards.
Monnickendam G; Zhu M; McKendrick J; Su Y
Value Health; 2019 Apr; 22(4):431-438. PubMed ID: 30975394
[TBL] [Abstract][Full Text] [Related]
17. Omnibus test for restricted mean survival time based on influence function.
Gu J; Fan Y; Yin G
Stat Methods Med Res; 2023 Jun; 32(6):1082-1099. PubMed ID: 37015346
[TBL] [Abstract][Full Text] [Related]
18. [Interpretation and Application of Restricted Mean Survival Time].
Hasegawa T
Gan To Kagaku Ryoho; 2022 Apr; 49(4):389-396. PubMed ID: 35444119
[TBL] [Abstract][Full Text] [Related]
19. On assessing survival benefit of immunotherapy using long-term restricted mean survival time.
Horiguchi M; Tian L; Uno H
Stat Med; 2023 Apr; 42(8):1139-1155. PubMed ID: 36653933
[TBL] [Abstract][Full Text] [Related]
20. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
Mukhopadhyay P; Ye J; Anderson KM; Roychoudhury S; Rubin EH; Halabi S; Chappell RJ
JAMA Oncol; 2022 Sep; 8(9):1294-1300. PubMed ID: 35862037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
